Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Vizimpro“
Suchtreffer
Begriffe & Kennungen
Vizimpro
Eintrag öffnenVizimpro · 4.1 Therapeutic indications · 1
Eintrag öffnenVizimpro · 4.3 Contraindications · 1
Eintrag öffnenVizimpro · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenVizimpro · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenVizimpro · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenVizimpro · 4.5 · Based on data from observations in 8 patients from Study A7471001, there was no apparent effect of local antac
Eintrag öffnenVizimpro · 4.5 · Based on in vitro data, dacomitinib may have the potential to inhibit the activity of P-glycoprotein (P-gp) (i
Eintrag öffnenVizimpro · 4.5 · Co-administration of dacomitinib and CYP2D6 substrates
Eintrag öffnenVizimpro · 4.5 · Co-administration of dacomitinib with agents that increase gastric pH
Eintrag öffnenVizimpro · 4.5 · Co-administration of single 45 mg oral dose of dacomitinib increased the mean exposure (AUClast and Cmax) of d
Eintrag öffnenVizimpro · 4.5 · Effect of dacomitinib on drug transporters
Eintrag öffnenVizimpro · 4.5 · The aqueous solubility of dacomitinib is pH dependent, with low (acidic) pH resulting in higher solubility. Da
Eintrag öffnenVizimpro · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenVizimpro · 4.8 Undesirable effects · 1
Eintrag öffnenVizimpro · 4.8 · * Fatal events were reported. a Hypokalaemia includes the following preferred terms (PTs): Blood potassium dec
Eintrag öffnenVizimpro · 4.8 · 10 Reporting of suspected adverse reactions
Eintrag öffnenVizimpro · 4.8 · 7 Adverse reactions leading to permanent discontinuation were reported in 6.7% of patients treated with dacomi
Eintrag öffnenVizimpro · 4.8 · 8 Table 3. Adverse reactions reported in dacomitinib clinical studies (N=255)
Eintrag öffnenVizimpro · 4.8 · Adverse reactions leading to dose reductions were reported in 52.2% of patients treated with dacomitinib. The
Eintrag öffnen